Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.43 |
| ▸ | FAAH | O00519 | 3/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.43 |
| ▸ | GSR | P00390 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | BLM | P54132 | 1/20 | 0.43 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 3/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.33 |
| ▸ | CNR1 | P21554 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9867939 | 0.87 | LMNA (0.42) | ALDH1A1FAAHTSHRMEN1KMT2A | |
| SCHEMBL7742941 | 0.83 | — | — | |
| SCHEMBL27963105 | 0.81 | FAAH (0.48) | ALDH1A1FAAHTSHRMEN1KMT2A | |
| SCHEMBL7579999 | 0.80 | GAA (0.45) | ALDH1A1FAAHTSHRMEN1KMT2A | |
| SCHEMBL9771629 | 0.79 | — | — | |
| SCHEMBL745861 | 0.78 | — | — | |
| SCHEMBL7731795 | 0.78 | — | — | |
| SCHEMBL3074569 | 0.78 | — | — | |
| SCHEMBL5674142 | 0.78 | — | — | |
| SCHEMBL8193236 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116332866-A | Preparation method of 2,2' -bis (2-oxazoline) | 浙江大学 | 2023-06-27 | — | — | CN | claimed |
| US-5026866-A | Synthesis of 2,2'-bis-Δ2 -oxazoline | ENICHEM ANIC S.P.A. (IT) | 1991-06-25 | — | — | US | claimed |
| EP-0375041-A2 | New synthesis of 2,2'-bis-delta2-oxazoline | ENICHEM S.p.A. (IT) | 1990-06-27 | — | — | EP | claimed |
| JP-58067680-A | — | — | None | — | — | JP | disclosed |
| JP-2215775-A | — | — | None | — | — | JP | disclosed |
| JP-56071051-A | — | — | None | — | — | JP | disclosed |
| CN-116332866-A | Preparation method of 2,2' -bis (2-oxazoline) | 浙江大学 | 2023-06-27 | — | — | CN | disclosed |
| CN-116332866-A | Preparation method of 2,2' -bis (2-oxazoline) | 浙江大学 | 2023-06-27 | — | — | CN | disclosed |
| US-20090306134-A1 | Muscarinic receptor antagonists | THERAVANCE BIOPHARMA R&D IP, LLC | 2009-12-10 | — | — | US | disclosed |
| US-20090306134-A1 | Muscarinic receptor antagonists | THERAVANCE BIOPHARMA R&D IP, LLC | 2009-12-10 | — | — | US | disclosed |
| EP-1457488-B1 | Intermediates for use in the preparation of urea compounds having muscarinic receptor antagonist activity | THERAVANCE INC (US) | 2009-08-12 | — | — | EP | disclosed |
| US-7173039-B2 | Protein kinase inhibitors | THERAVANCE, INC. (US) | 2007-02-06 | — | — | US | disclosed |
| US-6479498-B1 | COMPRISE 2-10 SODIUM CHANNEL LIGANDS COVALENTLY CONNECTED BY A LINKER OR LINKERS | THERAVANCE, INC. | 2002-11-12 | — | — | US | disclosed |
| US-6420354-B1 | Sodium channel drugs and uses | ADVANCED MEDICINE, INC. | 2002-07-16 | — | — | US | disclosed |
| EP-0375041-B1 | New synthesis of 2,2'-bis-delta2-oxazoline | ENICHEM SPA (IT) | 1994-03-09 | — | — | EP | disclosed |
| US-5026866-A | Synthesis of 2,2'-bis-Δ2 -oxazoline | ENICHEM ANIC S.P.A. (IT) | 1991-06-25 | — | — | US | disclosed |
| JP-H02215775-A | SYNTHESIS OF 2,2'-BIS-DELTA2-OXAZOLINE | ENICHEM ANIC SPA | 1990-08-28 | — | — | JP | disclosed |
| EP-0375041-A2 | New synthesis of 2,2'-bis-delta2-oxazoline | ENICHEM S.p.A. (IT) | 1990-06-27 | — | — | EP | disclosed |
| JP-S5867680-A | SYNTHESIS OF BIS-CYCLIC-IMINOETHER COMPOUND | TEIJIN LTD | 1983-04-22 | — | — | JP | disclosed |
| JP-S5671051-A | PREPARATION OF N,N'-BIS(2-CHLOROETHYL)OXAMIDE | TEIJIN LTD | 1981-06-13 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306134-A1 | Muscarinic receptor antagonists | CHRM3, CHRM5, CHRM2 | ALDH1A1 2335/4885FAAH 1081/4885TSHR 275/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.